Drug Trial Radar · NCT06550830
Clinical Trial of PCV24 in Children Aged 2-17 Years
Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
119
Actual
Start
Sep 7, 2024
Primary completion
Jun 25, 2025
Study completion Jun 25, 2025
Sponsor
- Lead sponsor
- Sinovac Life Sciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase Ia clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2-17 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, controlled combined with open-label phase Ia clinical trial.
Conditions
- Pneumococcal Infectious Disease
Interventions
Sinovac PCV24 formulation 1Biological
One dose of Sinovac PCV24 formulation 1(0.5mL)
Sinovac PCV24 formulation 2Biological
One dose of Sinovac PCV24 formulation 2(0.5mL)
Prevenar13®Biological
One dose of PCV13 manufactured by Pfizer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse reactionsTime frame: 0-30 days after vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine)
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.